PMOS—Expanding Diagnosis and Care Beyond Cysts and Cycles - Frankly Speaking Ep 505

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-505 Overview: The renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) reflects the true complexity of this diagnosis—a condition that extends beyond ovarian cysts and reproductive health. Listen in as we explore what drove the name change, how it better reflects the condition’s complexity, and what current evidence says about prevalence, risk, and whole-body management strategies for your patients. Episode resource links: Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S., Joham, A. E., Costello, M. F., ... & Piltonen, T. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet.   Tewari, S., Khalua, R. K., & Parida, S. (2026). Redefining polycystic ovary syndrome (PCOS) as Polyendocrine Metabolic Ovarian Syndrome (PMOS): implications for diagnosis, pathophysiology and clinical management. Int J Gynaecol Sci, 8(1), 17-25.   Tewari, S., Pramanik, P., Patra, T., & MK, M. (2026). From Reproductive Disorder to Metabolic Syndrome: The Evolution of Polycystic Ovary Syndrome (PCOS) into Polyendocrine Metabolic Ovarian Syndrome (PMOS). Journal of Pharmacognosy and Phytochemistry, 15(3), 329-337. Guest: Mariyan L. Montaque, DNP, FNP-BC   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.